Literature DB >> 20435891

Cathepsin H is an additional convertase of pro-granzyme B.

Michael E D'Angelo1, Phillip I Bird, Christoph Peters, Thomas Reinheckel, Joseph A Trapani, Vivien R Sutton.   

Abstract

The serine protease granzyme B (GrB) is the most potent proapoptotic cytotoxin of the granule exocytosis pathway of cytotoxic lymphocytes. GrB is synthesized as a zymogen (proGrB) and activated in cytotoxic granules by the lysosomal cysteine protease cathepsin C (CatC) which removes the N-terminal dipeptide Gly-Glu. It has been shown recently that mice lacking CatC nonetheless express significant residual GrB activity, indicating the presence of additional proGrB convertases. Here, we describe an assay to assess activation of proGrB and show that the amino-peptidase cathepsin H (CatH) has proGrB convertase activity in vitro, whereas dipeptidylpeptidase II does not. We generated mice lacking both CatC and CatH expression (CatCH(-/-)) and found that their lymphocytes have reduced convertase activity compared with those from CatC-deficient mice. Despite this, cytotoxic lymphocytes from CatCH(-/-) mice retain cytotoxic activity and some residual GrB activity. We conclude that CatH can act as an additional proGrB convertase and that other protease/s (apart from dipeptidylpeptidase II) must also possess convertase activity. This indicates a great deal of functional redundancy in GrB maturation, which would prevent pathogen-mediated immune suppression by via convertase inhibition.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20435891      PMCID: PMC2898313          DOI: 10.1074/jbc.M109.094573

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  26 in total

1.  Importance of the P4' residue in human granzyme B inhibitors and substrates revealed by scanning mutagenesis of the proteinase inhibitor 9 reactive center loop.

Authors:  J Sun; J C Whisstock; P Harriott; B Walker; A Novak; P E Thompson; A I Smith; P I Bird
Journal:  J Biol Chem       Date:  2001-02-01       Impact factor: 5.157

2.  Bcl-2 prevents apoptosis induced by perforin and granzyme B, but not that mediated by whole cytotoxic lymphocytes.

Authors:  V R Sutton; D L Vaux; J A Trapani
Journal:  J Immunol       Date:  1997-06-15       Impact factor: 5.422

3.  Expression and purification of recombinant human granzyme B from Pichia pastoris.

Authors:  J Sun; C H Bird; M S Buzza; K E McKee; J C Whisstock; P I Bird
Journal:  Biochem Biophys Res Commun       Date:  1999-08-02       Impact factor: 3.575

4.  Papillon-Lefèvre syndrome: correlating the molecular, cellular, and clinical consequences of cathepsin C/dipeptidyl peptidase I deficiency in humans.

Authors:  Christine T N Pham; Jennifer L Ivanovich; Sofia Z Raptis; Barbara Zehnbauer; Timothy J Ley
Journal:  J Immunol       Date:  2004-12-15       Impact factor: 5.422

5.  Dipeptidyl peptidase I is required for the processing and activation of granzymes A and B in vivo.

Authors:  C T Pham; T J Ley
Journal:  Proc Natl Acad Sci U S A       Date:  1999-07-20       Impact factor: 11.205

6.  Kinetic investigation of human dipeptidyl peptidase II (DPPII)-mediated hydrolysis of dipeptide derivatives and its identification as quiescent cell proline dipeptidase (QPP)/dipeptidyl peptidase 7 (DPP7).

Authors:  Marie-Berthe Maes; Anne-Marie Lambeir; Kambiz Gilany; Kristel Senten; Pieter Van der Veken; Barbara Leiting; Koen Augustyns; Simon Scharpé; Ingrid De Meester
Journal:  Biochem J       Date:  2005-03-01       Impact factor: 3.857

7.  Active and zymogen forms of granzyme B are constitutively released from cytotoxic lymphocytes in the absence of target cell engagement.

Authors:  Monica D Prakash; Catherina H Bird; Phillip I Bird
Journal:  Immunol Cell Biol       Date:  2008-12-16       Impact factor: 5.126

8.  Expression of recombinant human granzyme B. A processing and activation role for dipeptidyl peptidase I.

Authors:  M J Smyth; M J McGuire; K Y Thia
Journal:  J Immunol       Date:  1995-06-15       Impact factor: 5.422

9.  Activation of recombinant murine cytotoxic cell proteinase-1 requires deletion of an amino-terminal dipeptide.

Authors:  A Caputo; R S Garner; U Winkler; D Hudig; R C Bleackley
Journal:  J Biol Chem       Date:  1993-08-25       Impact factor: 5.157

10.  In vitro- and ex vivo-derived cytolytic leukocytes from granzyme A x B double knockout mice are defective in granule-mediated apoptosis but not lysis of target cells.

Authors:  M M Simon; M Hausmann; T Tran; K Ebnet; J Tschopp; R ThaHla; A Müllbacher
Journal:  J Exp Med       Date:  1997-11-17       Impact factor: 14.307

View more
  29 in total

1.  CTSH regulates β-cell function and disease progression in newly diagnosed type 1 diabetes patients.

Authors:  Tina Fløyel; Caroline Brorsson; Lotte B Nielsen; Michela Miani; Claus Heiner Bang-Berthelsen; Martin Friedrichsen; Anne Julie Overgaard; Lukas A Berchtold; Anna Wiberg; Pernille Poulsen; Lars Hansen; Silke Rosinger; Bernhard O Boehm; Ramesh Ram; Quang Nguyen; Munish Mehta; Grant Morahan; Patrick Concannon; Regine Bergholdt; Jens H Nielsen; Thomas Reinheckel; Matthias von Herrath; Allan Vaag; Decio Laks Eizirik; Henrik B Mortensen; Joachim Størling; Flemming Pociot
Journal:  Proc Natl Acad Sci U S A       Date:  2014-06-30       Impact factor: 11.205

Review 2.  Perforin and granzymes: function, dysfunction and human pathology.

Authors:  Ilia Voskoboinik; James C Whisstock; Joseph A Trapani
Journal:  Nat Rev Immunol       Date:  2015-06       Impact factor: 53.106

3.  Regulation of perforin activation and pre-synaptic toxicity through C-terminal glycosylation.

Authors:  Imran G House; Colin M House; Amelia J Brennan; Omer Gilan; Mark A Dawson; James C Whisstock; Ruby Hp Law; Joseph A Trapani; Ilia Voskoboinik
Journal:  EMBO Rep       Date:  2017-08-14       Impact factor: 8.807

Review 4.  Proteolytic networks in cancer.

Authors:  Steven D Mason; Johanna A Joyce
Journal:  Trends Cell Biol       Date:  2011-01-12       Impact factor: 20.808

5.  Mutations in LRPAP1 are associated with severe myopia in humans.

Authors:  Mohammed A Aldahmesh; Arif O Khan; Hisham Alkuraya; Nouran Adly; Shamsa Anazi; Ahmed A Al-Saleh; Jawahir Y Mohamed; Hadia Hijazi; Sarita Prabakaran; Marlene Tacke; Abdullah Al-Khrashi; Mais Hashem; Thomas Reinheckel; Abdullah Assiri; Fowzan S Alkuraya
Journal:  Am J Hum Genet       Date:  2013-07-03       Impact factor: 11.025

Review 6.  Cysteine cathepsin proteases: regulators of cancer progression and therapeutic response.

Authors:  Oakley C Olson; Johanna A Joyce
Journal:  Nat Rev Cancer       Date:  2015-12       Impact factor: 60.716

7.  Neutrophilic Cathepsin C Is Maturated by a Multistep Proteolytic Process and Secreted by Activated Cells during Inflammatory Lung Diseases.

Authors:  Yveline Hamon; Monika Legowska; Virginie Hervé; Sandrine Dallet-Choisy; Sylvain Marchand-Adam; Lise Vanderlynden; Michèle Demonte; Rich Williams; Christopher J Scott; Mustapha Si-Tahar; Nathalie Heuzé-Vourc'h; Gilles Lalmanach; Dieter E Jenne; Adam Lesner; Francis Gauthier; Brice Korkmaz
Journal:  J Biol Chem       Date:  2016-02-16       Impact factor: 5.157

8.  Cathepsin H functions as an aminopeptidase in secretory vesicles for production of enkephalin and galanin peptide neurotransmitters.

Authors:  Weiya Douglas Lu; Lydiane Funkelstein; Thomas Toneff; Thomas Reinheckel; Christoph Peters; Vivian Hook
Journal:  J Neurochem       Date:  2012-06-21       Impact factor: 5.372

9.  Cathepsin H indirectly regulates morphogenetic protein-4 (BMP-4) in various human cell lines.

Authors:  Matija Rojnik; Zala Jevnikar; Bojana Mirkovic; Damjan Janes; Nace Zidar; Danijel Kikelj; Janko Kos
Journal:  Radiol Oncol       Date:  2011-10-08       Impact factor: 2.991

10.  Human NK cell lytic granules and regulation of their exocytosis.

Authors:  Konrad Krzewski; John E Coligan
Journal:  Front Immunol       Date:  2012-11-09       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.